



IDFC LARGE CAP FUND

Large Cap Fund - An open ended equity scheme predominantly investing in large cap stocks

FUND PHILOSOPHY*

The fund aims to generate steady returns by investing in the leading stocks of the chosen sectors, predominantly amongst the large cap universe. The portfolio approach is based on a robust three pillar strategy, namely:

Buying the right sectors – Identifying and investing in the right sectors with the flexibility to have large deviations from the benchmark sector weights.

Buying the sector leaders - Investing in the sector leader companies having strong fundamentals, solid execution track record as well as resilient balance sheet to withstand any cyclical downturns.

Tactical allocation to mid/small caps – Opportunistic allocation to take advantage of any mispriced opportunities or a benevolent risk-on environment.

The fund has a “Growth” and “Quality” oriented investment style, and is focused on companies having a strong visibility of earnings growth coupled with healthy return on capital employed.

OUTLOOK

During the month of January’22, equity markets across the globe were largely impacted by US Fed utterances regarding interest rates and balance sheet contraction. Markets roiled at the prospects of tightening liquidity and a phase of rising interest rates. On domestic front, the Union Budget 2022-23 was largely viewed as a positive by equity markets. The equity markets took solace from the conservative assumptions for revenue collections going in to FY23 and modest expenditure growth with a clear tilt on capital spending across, roads; railways & affordable housing sectors. The early birds in the earnings season have reported a mixed bag – robust sales growth and outlook, shrinking margin due to higher input prices and inability to completely pass on these cost surges. Unseasonal rains had also dampened demand in certain segments/sectors. As a result FY22 & 23 estimates may be downgraded marginally, though analysts seemed to be re-assured by management commentary and FY24 estimates remain largely unchanged.

FUND FEATURES: (Data as on 31st January’22)

Category: Large Cap

Monthly Avg AUM: ₹1,001.72 Crores

Inception Date: 9th June 2006

Fund Manager: Mr. Sumit Agrawal and Mr. Arpit Kapoor (w.e.f. 01/03/2017)

Other Parameters:

Beta: 0.88

R Squared: 0.96

Standard Deviation (Annualized): 19.26%

Benchmark: S&P BSE 100 TRI
(w.e.f. 18/04/2017)

Minimum Investment Amount: ₹5,000/-
and any amount thereafter.

Exit Load:

- If redeemed/switched out within 365 days from the date of allotment:
 - > Up to 10% of investment: Nil,
 - > For remaining investment: 1% of applicable NAV
- If redeemed / switched out after 365 days from date of allotment: Nil.
(w.e.f. 25th June 2021)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)

Options Available: Growth, IDCW® (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

PLAN	IDCW® RECORD DATE	₹/UNIT	NAV
REGULAR	22-Jul-21	0.89	17.8600
	16-Mar-20	1.04	12.1800
	19-Mar-19	0.77	15.1200
DIRECT	22-Jul-21	1.11	22.3200
	16-Mar-20	1.27	14.9900
	19-Mar-19	0.95	18.4400

Face Value per Unit (in ₹) is 10

Income Distribution cum capital withdrawal is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of Income Distribution cum capital withdrawal, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

®Income Distribution cum capital withdrawal

Ratios calculated on the basis of 3 years history of monthly data.


The above mentioned is the current strategy of the Fund Manager. However, asset allocation and investment strategy shall be within broad parameters of Scheme Information Document.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

Name of the Instrument	% to NAV	Name of the Instrument	% to NAV
Equity and Equity related Instruments	97.46%	SRF	1.12%
Banks	31.12%	Pharmaceuticals	2.86%
ICICI Bank	9.64%	Gland Pharma	1.49%
State Bank of India	8.27%	Divi's Laboratories	1.37%
HDFC Bank	7.38%	Construction Project	2.34%
Axis Bank	3.24%	Larsen & Toubro	2.34%
Kotak Mahindra Bank	2.59%	Consumer Durables	2.06%
Software	18.86%	Titan Company	1.06%
Infosys	6.74%	Voltas	1.00%
Tata Consultancy Services	3.87%	Cement & Cement Products	1.93%
Larsen & Toubro Infotech	1.90%	UltraTech Cement	1.93%
HCL Technologies	1.28%	Construction	1.85%
Mphasis	1.07%	PSP Projects	1.85%
Coforge	1.02%	Industrial Products	1.82%
L&T Technology Services	1.01%	Bharat Forge	1.82%
MindTree	1.01%	Healthcare Services	1.81%
Tech Mahindra	0.96%	Apollo Hospitals Enterprise	1.81%
Finance	7.84%	Non - Ferrous Metals	1.43%
HDFC	4.13%	Hindalco Industries	1.43%
Bajaj Finance	3.71%	Retailing	1.34%
Consumer Non Durables	5.71%	Avenue Supermarts	1.34%
Hindustan Unilever	2.52%	Textile Products	1.10%
Asian Paints	1.15%	Page Industries	1.10%
Godrej Consumer Products	1.09%	Insurance	1.09%
Nestle India	0.95%	Bajaj Finserv	1.09%
Petroleum Products	4.95%	Telecom - Services	1.00%
Reliance Industries	4.95%	Bharti Airtel	1.00%
Auto	4.30%	Leisure Services	0.97%
Maruti Suzuki India	2.22%	Jubilant Foodworks	0.97%
Tata Motors	1.06%	Corporate Bond	0.004%
Mahindra & Mahindra	1.02%	Britannia Industries	AAA 0.004%
Chemicals	3.07%	Net Cash and Cash Equivalent	2.53%
Anupam Rasayan India	1.95%	Grand Total	100.00%



SECTOR ALLOCATION



<p>Scheme risk-o-meter</p> <p>Investors understand that their principal will be at Very High risk</p>	<p>This product is suitable for investors who are seeking*</p> <ul style="list-style-type: none"> To create wealth over long term. Investment predominantly in equity and equity related instruments of the large cap companies. <p>*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.</p>	<p>Benchmark risk-o-meter</p> <p>S&P BSE 100 TRI</p>
--	---	---